The Impact of Tariffs on the Life Sciences Sector

As governments implement tariffs to protect domestic industries and address trade imbalances, the implications for pharmaceuticals, clinical trials, and medical devices are profound.

This article reflects the discussion in a recent live round table webinar with NSF experts across Clinical, Medical Devices, Pharma Biotech and Government Affairs. The webinar discussed the multifaceted effects of tariffs on the life sciences sector, exploring their origins, current status, and potential future developments, and what strategic and practical steps life science companies can do today to get and stay ahead.

Tariffs are taxes imposed by governments on imported goods, aimed at making foreign products more expensive and thus encouraging consumers to buy domestically produced items. The rationale behind tariffs often includes:

• Protecting local industries: By increasing the cost of imports, tariffs can help domestic manufacturers compete more effectively.
• Generating revenue: Tariffs serve as a source of income for governments, contributing to national budgets.
• Addressing trade Deficits: Tariffs can be used as a tool to reduce trade imbalances by discouraging imports.

The implementation of tariffs can lead to a ripple effect throughout the economy, influencing prices, supply chains, and ultimately, consumer behaviour.

As of 2025, the United States has seen a significant shift in its trade policy under the America First Trade Policy initiated by the current administration. This policy has led to the introduction of various tariffs, including a universal 10% tariff on a wide range of goods. Notably, while pharmaceuticals and active pharmaceutical ingredients (APIs) are currently exempt from this tariff, medical devices are not. This distinction is crucial for stakeholders in the life sciences sector.

• Presidential memoranda: The administration has issued several memoranda directing investigations into trade deficits and proposing remedies, including tariffs.
• Reciprocal tariffs: The introduction of reciprocal tariffs has raised concerns among manufacturers, particularly those reliant on international supply chains.
• National security investigations: Ongoing investigations into the impact of trade on national security, particularly concerning pharmaceuticals and semiconductors, could lead to further regulatory changes.

The pharmaceutical industry is particularly sensitive to tariff changes due to its reliance on global supply chains for APIs and other critical components. While current tariffs do not directly affect the importation of investigational products under an Investigational New Drug (IND) or Investigational Device Exemption (IDE), they can still impact the overall cost structure of clinical trials and drug development.

• Increased costs: Tariffs can lead to higher costs for importing trial supplies, equipment, and raw materials, which may ultimately be passed on to consumers.
• Supply chain diversification: Companies are increasingly looking to diversify their supply chains to mitigate the risks associated with tariffs, particularly those sourcing from countries like China.

Pharmaceutical companies are adopting various strategies to navigate the tariff landscape:

• Evaluating supply sources: Companies are assessing their supply chains to identify alternative sources for APIs that may incur lower tariffs.
• Regulatory planning: Firms are proactively engaging with regulatory bodies to understand the implications of potential tariff changes on their product submissions.

Clinical trials are a critical component of the drug development process, and the rising costs associated with tariffs can pose significant challenges for sponsors, particularly smaller companies.

• Regulatory changes: New guidelines and regulations, such as the ICH E6 R3, are set to increase the complexity and cost of clinical trials.
• Tariff-related costs: While investigational products may be imported duty-free, the costs of trial supplies and equipment can still be affected by tariffs.

To address these challenges, companies are exploring several strategies:

• Vendor diversification: Engaging with global Contract Research Organisations (CROs) to rethink vendor strategies and diversify supply chains.
• Scenario planning: Developing risk models to anticipate potential disruptions and prepare contingency plans.

The medical device sector is one of the most globalised industries, and as such, it faces unique challenges in the context of tariffs. The imposition of tariffs can significantly impact the cost structure and operational strategies of medical device manufacturers.

• Increased tariffs on imports: Medical devices are subject to tariffs that can affect their pricing and competitiveness in the market.
• Retaliatory tariffs: Manufacturers must also contend with retaliatory tariffs imposed by other countries, further complicating the supply chain landscape.

To navigate these challenges, companies in the medical device sector are implementing various strategies:

• Internal operations review: Conducting thorough reviews of material classifications and import processes to ensure compliance and minimise costs.
• Tariff reengineering: Exploring opportunities to insource certain operations to reduce the value of imported materials and mitigate tariff impacts.

Trade associations play a vital role in advocating for the interests of the life sciences sector in the face of changing tariff policies. Organisations such as AVAMed and the American Manufacturing Association work to represent the collective voice of the industry.

• Petitioning for exclusions: Trade associations actively engage with government officials to seek exclusions from tariffs for specific products or materials.
• Providing resources: These organisations offer resources and guidance to help companies navigate the complexities of tariff regulations.

As the global trade environment continues to evolve, the life sciences sector must remain vigilant and adaptable. The potential for new tariffs or changes to existing policies necessitates proactive planning and strategic foresight.

• Engaging with experts: Companies should seek guidance from industry experts to develop robust strategies for managing tariff-related risks.
• Utilising technology: Leveraging artificial intelligence and data analytics can help organisations identify vulnerabilities in their supply chains and optimise their operations.

The impact of tariffs on the life sciences sector is multifaceted, influencing everything from drug development to clinical trials and medical device manufacturing. As companies navigate this complex landscape, it is essential to adopt proactive strategies that prioritise resilience and adaptability. By engaging with trade associations, diversifying supply chains, and leveraging technology, organisations can position themselves for success in an increasingly uncertain global trade environment.

In summary, while tariffs present challenges, they also offer opportunities for innovation and strategic growth within the life sciences sector. By staying informed and prepared, companies can effectively mitigate risks and capitalise on emerging trends in the industry.

Through its comprehensive services, deep industry expertise, and collaborative approach, NSF is well-positioned to support life sciences companies as they navigate these obstacles and capitalise on the numerous opportunities that lie ahead. Schedule a free consultation call with us today.